Product Pathways - Cell Cycle / Checkpoint
DYRK2 Antibody #8143
|8143S||100 µl (10 western blots)||---||In Stock||---|
|8143||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat, Monkey||Endogenous||66, 60||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Species predicted to react based on 100% sequence homology: Bovine, Dog, Pig.
Specificity / Sensitivity
DYRK2 Antibody recognizes endogenous levels of total DYRK2 protein. This antibody recognizes both the 66 and 60 kDa splice variants.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly545 of human DYRK2 protein. Antibodies are purified by protein A and peptide affinity chromatography.
The DYRK family includes several dual-specificity tyrosine-phosphorylated and regulated kinases capable of phosphorylating proteins at both Tyr and Ser/Thr residues (1). The DYRK family was identified based on homology to the yeast Yak1 (2) and the Drosophila minibrain (mnb) kinases (3). Seven mammalian isoforms have been discovered, including DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4, and DYRK4B. Differences in substrate specificity, expression, and subcellular localization are seen across the DYRK family (4,5). All DYRK proteins have a Tyr-X-Tyr motif in the catalytic domain activation loop; phosphorylation of the second Tyr residue (e.g. Tyr312 of DYRK1A) is necessary for kinase activity. DYRKs typically autophosphorylate the Tyr residue within their activation loop, but phosphorylate substrates at Ser and Thr residues (1,6).
DYRK2 is thought to play a role in checkpoint control of the cell cycle. DYRK2 can phosphorylate p53 at Ser46 following cellular damage, leading to activation of the apoptotic response (7). Overexpression of DYRK2 has also been reported in esophageal and lung adenocarcinomas (8), and its expression levels were shown to be predictive of chemotherapy treatment outcomes in non-small cell lung cancer (9).
- Becker, W. and Joost, H.G. (1999) Prog. Nucleic Acid Res. Mol. Biol. 62, 1-17.
- Garrett, S. and Broach, J. (1989) Genes Dev. 3, 1336-1348.
- Tejedor, F. et al. (1995) Neuron 14, 287-301.
- Kentrup, H. et al. (1996) J. Biol. Chem. 271, 3488-3495.
- Becker, W. et al. (1998) J. Biol. Chem. 273, 25893-25902.
- Lochhead, P.A. et al. (2005) Cell 121, 925-936.
- Taira, N. et al. (2007) Mol Cell 25, 725-38.
- Miller, C.T. et al. (2003) Cancer Res 63, 4136-43.
- Yamashita, S. et al. (2009) Anticancer Res 29, 2753-7.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7727 Biotinylated Protein Ladder Detection Pack
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 2703 DYRK1B Antibody
- 2771 DYRK1A Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7003 20X LumiGLO® Reagent and 20X Peroxide
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.